Inventor · disambiguated record
Mary Kleppe
Also filed as: KLEPPE MARY · KLEPPE MARY S
9 granted patents·16 pending applications·133 citations·filing 2003–2024
89Inventor score
Top patents by PatentIndex Score
25 records- 0193US12066246B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2023·Granted Aug 20, 2024·2 cites·20 claims
- 0293US7244709B2Compositions and methods for enhanced mucosal delivery of parathyroid hormoneNASTECH PHARM CO·Filed 2005·Granted Jul 17, 2007·26 cites·32 claims
- 0392US11525629B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2021·Granted Dec 13, 2022·4 cites·20 claims
- 0491US11713922B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2022·Granted Aug 1, 2023·3 cites·15 claims
- 0591US7157426B2Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesityNASTECH PHARM CO·Filed 2004·Granted Jan 2, 2007·40 cites·19 claims
- 0690US7435720B2Compositions and methods for enhanced mucosal delivery of parathyroid hormoneMDRNA INC·Filed 2006·Granted Oct 14, 2008·16 cites·5 claims
- 0786US12449198B2Target residual moisture content for lyophilized drug productREGENERON PHARMA·Filed 2024·Granted Oct 21, 2025·0 cites·19 claims
- 0886US7186691B2Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesityNASTECH PHARM CO·Filed 2003·Granted Mar 6, 2007·22 cites·27 claims
- 0984US7229966B2Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesityNASTECH PHARM CO·Filed 2004·Granted Jun 12, 2007·20 cites·41 claims
- 1069US2025179177A1Stable antibody formulationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1162US2025109905A1Lyophilization using controlled nucleationREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1260US2007244049A1Compositions and methods for enhanced mucosal delivery of parathyroid hormoneNASTECH PHARM CO·Filed 2007·Application pending·0 cites
- 1360US2024175027A1Anti-c5 antibody/c5 irna co-formulations and combination therapiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1458US2007129299A1Compositions and methods for enhanced mucosal delivery of pyy peptideNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 1558US2007197437A1Compositions for enhanced epithelial permeation of y2 receptor-binding peptidesNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 1654US2008318837A1Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating PeptideNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 1753US2006074025A1Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailabilityNASTECH PHARM CO·Filed 2005·Application pending·0 cites
- 1852US2010210506A1Intranasal administration of rapid acting insulinMDRNA INC·Filed 2006·Application pending·0 cites
- 1952US2007161563A1A device for enhanced epithelial permeation of y2 receptor-binding peptidesNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 2050US2021046182A1High concentration anti-c5 formulationsREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2150US2010184688A1Compositions and methods for enhanced mucosal delivery of parathyroid hormoneMDRNA INC·Filed 2010·Application pending·0 cites
- 2245US2007213270A1Peptide yy formulations having increased stability and resistance to microbial agentsCOSTANTINO HENRY R·Filed 2005·Application pending·0 cites
- 2344US2009042790A1Transmucosal delivery of peptide derivativesNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 2442US2007232537A1Intranasal pyy formulations with improved transmucosal pharmacokineticsNASTECH PHARM CO·Filed 2006·Application pending·0 cites
- 2540US2009054326A1Formulations for enhanced mucosal delivery of pyyNASTECH PHARM CO·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mary Kleppe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →